

ALCOHOL USE DISORDER OUTPATIENT PRESCRIPTION

Weight (kg)

R Date (dd/mm/yyyy) Allergies				
First-line treatment				
 naltrexone 25 mg PO DAILY × 3 days, then naltrexone 50 mg PO DAILY Contraindicated if active opioid use disorder OR prescription opioids for pain, acute hepatitis, liver enzymes greater than 5 times normal, or liver failure 			Quantity	# Refill
 acamprosate 666 mg PO TID For patients with CrCl greater than 50 mL/min 			Quantity	# Refill
 acamprosate 333 mg PO TID For patients with CrCl 30 to 50 mL/min. Naltrexone is recommended first-line agent if renal impairment. 			Quantity	# Refill
Second-line treatment				
 gabapentin 300 mg PO TID × 24 hours, then if well tolerated increase to 600 mg PO TID Use caution if renal impairment, dose reductions required 			Quantity	# Refill
 topiramate 25 mg PO QHS × 7 days, then increase to 25 mg PO BID × 7 days, then increase to 50 mg PO BID Use caution if renal impairment, dose reductions required 			Quantity	□ # Refill
□ Other			Quantity	# Refill
Withdrawal managemer	nt if low risk o	f complicated withdrawal		
 □ gabapentin 300 to 600 mg PO QID PRN withdrawal symptoms • Use caution if renal impairment, dose reductions required 			Quantity	# Refill
Date (dd/mm/yyyy) Time (24 hour) Physician Signature				Printed name or College ID#

805003 Jun 15-23 Page 1 of 1

Patient consents to try Pharmacologic Treatment for their AUD



